FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186606314> ?p ?o ?g. }

• W3186606314 endingPage "1575" @default.
• W3186606314 startingPage "1575" @default.
• W3186606314 abstract "Acute myeloid leukemia (AML) is a hematological malignancy with a low remission rate and high recurrence rate. Overexpression of the antiapoptotic protein Bcl-2 is associated with a lower overall survival rate in AML patients. Venetoclax (ABT199) is a selective inhibitor of Bcl-2 that has a significant effect in AML, but single-drug resistance often occurs due to the high expression of Mcl-1 protein. Studies have confirmed that chidamide can downregulate the expression levels of Bcl-2 and Mcl-1 and induce apoptosis.This study aimed to use AML cell lines and primary cells to study the effects of venetoclax and chidamide combination therapy on AML cell apoptosis, the cell cycle, and changes in related signaling pathways in vitro; establish an AML mouse model to observe the efficacy and survival time of combination therapy in vivo; and analyze the drug effects with multi-omics sequencing technology. The changes in gene and protein expression before and after treatment were examined to clarify the molecular mechanism driving the synergistic effect of the two drugs.(I) Both venetoclax and chidamide promoted apoptosis in AML cell lines and primary cells in a time- and concentration-dependent manner. The effect was further enhanced when the two drugs were combined, and a synergistic effect was observed (combination index <1). (II) At both the mRNA and protein levels, the expression of Mcl-1 was upregulated by venetoclax and downregulated by chidamide, and the expression of Mcl-1 decreased further after combination treatment. (III) Transcriptome sequencing showed that differentially expressed genes in the combination group compared with the venetoclax monotherapy group were mainly enriched in the PI3K-AKT pathway and JAK2/STAT3 pathway. Moreover, qRT-PCR and Western blot confirmed these results. (IV) The combination therapy group exhibited significantly inhibited disease progression and a prolonged survival time among AML mice.Chidamide combined with venetoclax synergistically promoted apoptosis in AML cell lines and primary cells by inhibiting activation of the PI3K/AKT pathway and JAK2/STAT3 pathway." @default.
• W3186606314 created "2021-08-02" @default.
• W3186606314 creator A5019331905 @default.
• W3186606314 creator A5020088480 @default.
• W3186606314 creator A5027433551 @default.
• W3186606314 creator A5052368006 @default.
• W3186606314 creator A5068796555 @default.
• W3186606314 creator A5078143614 @default.
• W3186606314 date "2021-10-01" @default.
• W3186606314 modified "2023-09-23" @default.
• W3186606314 title "Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism" @default.
• W3186606314 cites W1966539065 @default.
• W3186606314 cites W1981745443 @default.
• W3186606314 cites W1989336886 @default.
• W3186606314 cites W1989949054 @default.
• W3186606314 cites W2010288516 @default.
• W3186606314 cites W2020175157 @default.
• W3186606314 cites W2026064268 @default.
• W3186606314 cites W2046345187 @default.
• W3186606314 cites W2062535897 @default.
• W3186606314 cites W2066404900 @default.
• W3186606314 cites W2086290282 @default.
• W3186606314 cites W2097400599 @default.
• W3186606314 cites W2102461774 @default.
• W3186606314 cites W2125963106 @default.
• W3186606314 cites W2133591242 @default.
• W3186606314 cites W2135080095 @default.
• W3186606314 cites W2140192991 @default.
• W3186606314 cites W2144664431 @default.
• W3186606314 cites W2151089049 @default.
• W3186606314 cites W2151131019 @default.
• W3186606314 cites W2237124828 @default.
• W3186606314 cites W2275197865 @default.
• W3186606314 cites W2314703289 @default.
• W3186606314 cites W2338674998 @default.
• W3186606314 cites W2512335901 @default.
• W3186606314 cites W2517675534 @default.
• W3186606314 cites W2519124868 @default.
• W3186606314 cites W2560346983 @default.
• W3186606314 cites W2563332856 @default.
• W3186606314 cites W2570901792 @default.
• W3186606314 cites W2593230508 @default.
• W3186606314 cites W2601168549 @default.
• W3186606314 cites W2605114805 @default.
• W3186606314 cites W2741462465 @default.
• W3186606314 cites W2765155026 @default.
• W3186606314 cites W2773114573 @default.
• W3186606314 cites W2774533007 @default.
• W3186606314 cites W2778260635 @default.
• W3186606314 cites W2783500974 @default.
• W3186606314 cites W2783685735 @default.
• W3186606314 cites W2887452072 @default.
• W3186606314 cites W2889850618 @default.
• W3186606314 cites W2891173371 @default.
• W3186606314 cites W2898284215 @default.
• W3186606314 cites W2958663663 @default.
• W3186606314 cites W2992597464 @default.
• W3186606314 cites W3025975123 @default.
• W3186606314 cites W3112156395 @default.
• W3186606314 cites W3156838311 @default.
• W3186606314 cites W3159998419 @default.
• W3186606314 doi "https://doi.org/10.21037/atm-21-5066" @default.
• W3186606314 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8576699" @default.
• W3186606314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34790781" @default.
• W3186606314 hasPublicationYear "2021" @default.
• W3186606314 type Work @default.
• W3186606314 sameAs 3186606314 @default.
• W3186606314 citedByCount "6" @default.
• W3186606314 countsByYear W31866063142022 @default.
• W3186606314 countsByYear W31866063142023 @default.
• W3186606314 crossrefType "journal-article" @default.
• W3186606314 hasAuthorship W3186606314A5019331905 @default.
• W3186606314 hasAuthorship W3186606314A5020088480 @default.
• W3186606314 hasAuthorship W3186606314A5027433551 @default.
• W3186606314 hasAuthorship W3186606314A5052368006 @default.
• W3186606314 hasAuthorship W3186606314A5068796555 @default.
• W3186606314 hasAuthorship W3186606314A5078143614 @default.
• W3186606314 hasBestOaLocation W31866063141 @default.
• W3186606314 hasConcept C104317684 @default.
• W3186606314 hasConcept C127561419 @default.
• W3186606314 hasConcept C150194340 @default.
• W3186606314 hasConcept C162317418 @default.
• W3186606314 hasConcept C185592680 @default.
• W3186606314 hasConcept C190283241 @default.
• W3186606314 hasConcept C203014093 @default.
• W3186606314 hasConcept C207001950 @default.
• W3186606314 hasConcept C2777938653 @default.
• W3186606314 hasConcept C2778461978 @default.
• W3186606314 hasConcept C2778729363 @default.
• W3186606314 hasConcept C2779282312 @default.
• W3186606314 hasConcept C2779675984 @default.
• W3186606314 hasConcept C29537977 @default.
• W3186606314 hasConcept C502942594 @default.
• W3186606314 hasConcept C54355233 @default.
• W3186606314 hasConcept C55493867 @default.
• W3186606314 hasConcept C86803240 @default.
• W3186606314 hasConceptScore W3186606314C104317684 @default.
• W3186606314 hasConceptScore W3186606314C127561419 @default.

• next